SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist.
AUTOR(ES)
Ohlstein, E H
RESUMO
An extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist, SB 209670, has been synthesized and characterized. SB 209670, which was rationally designed using conformational models of ET-1, selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki = 0.2 and 18 nM, respectively). SB 209670 produces concentration-dependent inhibition of ET-1-mediated vasoconstriction in isolated vascular tissues and in vivo following either intravenous or intraduodenal administration. SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty. SB 209670 will be useful in characterizing and classifying the physiological and pathophysiological effects of ET.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44543Documentos Relacionados
- Pharmacological properties of a potent and selective nonpeptide substance P antagonist.
- The nonpeptide WIN 64338 is a bradykinin B2 receptor antagonist.
- Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
- Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.
- Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.